These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25997855)

  • 1. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.
    Hong JY; Park YH; Choi MK; Jung HA; Lee SJ; Ahn JS; Im YH
    Clin Breast Cancer; 2015 Oct; 15(5):e287-92. PubMed ID: 25997855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
    Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SJ; Choi YL; Park YH; Kim ST; Cho EY; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
    Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
    Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
    Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère JF; Montestruc F; Mouri Z; Namer M
    Eur J Cancer; 2004 Mar; 40(4):536-42. PubMed ID: 14962720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.
    Lv F; Cao J; Liu Z; Wang Z; Zhang J; Zhang S; Wang L; Zhao X; Shao Z; Wang B; Hu X
    PLoS One; 2015; 10(3):e0118607. PubMed ID: 25768439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
    Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
    Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
    Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
    J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
    Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
    Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
    Lin PC; Wang WS; Yang MH; Yen CC; Chao TC; Hsiao LT; Chen PM
    J Chin Med Assoc; 2006 Jul; 69(7):304-9. PubMed ID: 16903643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.